JLE

European Journal of Dermatology

MENU

Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7 Volume 32, issue 2, March-April 2022

Figure 1

Proportion of patients with and without itch improvement achieving DLQI endpoints at Week 16. AD: atopic dermatitis; DLQI: Dermatology Life Quality Index. ***p<0.001. Itch improvement is defined as a ≥4-point decrease in the Itch Numeric Rating Scale at Week 16. Analysis included patients with baseline DLQI scores ≥4 or ≥1, depending on the outcome assessed. Logistic regression models were used with terms for baseline disease severity (vIGA-AD), baseline value, region, treatment group, itch/sleep improvement (yes or no), and the interaction of treatment and itch/sleep response; non-responder imputation was applied for missing data.

Figure 2

Mean change from baseline in work productivity and daily activity impairment in patients with and without itch improvement. Scores are based on Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis. ***p<0.001. Itch improvement is defined as a ≥4-point decrease in the Itch Numeric Rating Scale at Week 16. Absenteeism, presenteeism, and overall work impairment were measured in employed patients only (n = 191).

Figure 3

Proportion of patients with and without sleep improvement achieving DLQI endpoints at Week 16. AD: atopic dermatitis; DLQI: Dermatology Life Quality Index. **p<0.01, ***p<0.001. Sleep improvement is defined as a ≥1.5-point decrease in Atopic Dermatitis Sleep Scale Item 2 score at Week 16. Analysis included patients with baseline DLQI scores ≥4, or ≥1, depending on the outcome assessed. Logistic regression models were used with terms for baseline disease severity (vIGA-AD), baseline value, region, treatment group, itch/sleep improvement (yes or no), and the interaction of treatment and itch/sleep response; non-responder imputation was applied for missing data.

Figure 4

Mean change from baseline in work productivity and daily activity impairment in patients with and without sleep improvement. Scores are based on Work Productivity and Activity Impairment Questionnaire–Atopic Dermatitis. *p<0.05, ***p<0.001. Sleep improvement is defined as a ≥1.5-point decrease in Atopic Dermatitis Sleep Scale Item 2 score at Week 16. Absenteeism, presenteeism, and overall work impairment were measured in employed patients only (n = 93).